US And EU Systems For Personalized Medicine: Paths Diverging?
Executive Summary
There are changes afoot in the regulation and reimbursement policy for IVDs in the EU and US. When it comes to personalized medicine, and companion diagnostics in particular, are the two markets becoming more polarized? Medtech Insight asked US- and EU-based attorneys at Hogan Lovells.
You may also be interested in...
Could EU's New HTA Proposal Promote EU-Wide Reimbursement Of Personalized Medicine?
Personalized medicine has yet to really take off in the EU. One of the main barriers are the fragmented rules around reimbursement. Could the European Commission's health technology assessment proposal help?
Labs, Test Makers Urge Congress To Pass Diagnostic Reforms
More than 80 industry, laboratory, health-care provider and patient groups sent a letter to two congressional committees, urging them to advance a bill to modernize the current way FDA regulates diagnostic tests, including possibly a new regulated product category that combines laboratory developed tests and in vitro diagnostics.
Medicare Finalizes NGS Test Coverage For Advanced Cancers, Drops Evidence-Collection Provision
The US Centers for Medicare and Medicaid Services said on March 16 that it will cover next-generation sequencing diagnostic laboratory tests for advanced cancers, broadening its final determination to cover use in relapsed, refractory and stage III cancers, while dropping "coverage with evidence development" conditions.